Literature DB >> 7702373

Chronic idiopathic thrombocytopenic purpura: incidence, treatment, and outcome.

M M Reid1.   

Abstract

In order to determine incidence, outcome, trends in management and natural history, data on 92 children with chronic idiopathic thrombocytopenic purpura (ITP), comprising 66 from a single centre's experience between 1950 and 1980 and all 26 presenting from a defined population between 1984 and 1994, have been analysed. Its incidence, calculated from the population based group, is 0.46/10(5) children per year. Twenty nine of 34 (85%) remitted after splenectomy. Short initial histories predicted response to splenectomy. Splenectomy was offered only half as frequently in the last 10 years as in the 30 year, single centre group of children. Most (39 cases) of those not offered or successfully treated by splenectomy recovered spontaneously. The predicted spontaneous remission rate in 85 with adequate follow up data is 61% after 15 years. No other form of active treatment was of lasting benefit. No death solely attributable to chronic ITP occurred. The high spontaneous recovery rate, low mortality, and generally benign outcome may encourage a less interventionist approach to management.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7702373      PMCID: PMC1511010          DOI: 10.1136/adc.72.2.125

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  14 in total

1.  Guidelines for management of idiopathic thrombocytopenic purpura. The British Paediatric Haematology Group.

Authors:  O B Eden; J S Lilleyman
Journal:  Arch Dis Child       Date:  1992-08       Impact factor: 3.791

2.  Chronic idiopathic thrombocytopenic purpura: the pediatrician's dilemma.

Authors:  J S Lilleyman
Journal:  Pediatr Hematol Oncol       Date:  1990       Impact factor: 1.969

3.  Idiopathic thrombocytopenic purpura: an epidemiologic study.

Authors:  A T Lammi; V A Lovric
Journal:  J Pediatr       Date:  1973-07       Impact factor: 4.406

4.  Splenunculectomy in thrombocytopenic purpura.

Authors:  M M Reid; P W Saunders; J D Fenwick; W Walker
Journal:  Arch Dis Child       Date:  1986-02       Impact factor: 3.791

5.  Chronic thrombocytopenia in childhood.

Authors:  M E Ramos; A J Newman; S Gross
Journal:  J Pediatr       Date:  1978-04       Impact factor: 4.406

6.  Chronic idiopathic thrombocytopenic purpura: primum non nocere.

Authors:  J Chessells
Journal:  Arch Dis Child       Date:  1989-09       Impact factor: 3.791

Review 7.  Management of childhood idiopathic thrombocytopenic purpura.

Authors:  J S Lilleyman
Journal:  Br J Haematol       Date:  1983-05       Impact factor: 6.998

8.  Idiopathic thrombocytopenic purpura in childhood.

Authors:  S I Choi; P D McClure
Journal:  Can Med Assoc J       Date:  1967-09-09       Impact factor: 8.262

9.  Idiopathic thrombocytopenia, initial illness and long term follow up.

Authors:  R W Walker; W Walker
Journal:  Arch Dis Child       Date:  1984-04       Impact factor: 3.791

10.  Seventeen years of experience with chronic idiopathic thrombocytopenic purpura in childhood. Is therapy always better?

Authors:  S Aronis; H Platokouki; A Mitsika; S Haidas; A Constantopoulos
Journal:  Pediatr Hematol Oncol       Date:  1994 Sep-Oct       Impact factor: 1.969

View more
  9 in total

Review 1.  Idiopathic thrombocytopenic purpura.

Authors:  P H Bolton-Maggs
Journal:  Arch Dis Child       Date:  2000-09       Impact factor: 3.791

Review 2.  Treatment of immune thrombocytopenic purpura in children : current concepts.

Authors:  Aziza T Shad; Corina E Gonzalez; S G Sandler
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

3.  Prevalence of primary immune thrombocytopenia in Oklahoma.

Authors:  Deirdra R Terrell; Laura A Beebe; Barbara R Neas; Sara K Vesely; Jodi B Segal; James N George
Journal:  Am J Hematol       Date:  2012-06-05       Impact factor: 10.047

4.  Characterization of chronic idiopathic thrombocytopenic purpura in Japanese children: a retrospective multi-center study.

Authors:  Masaru Kubota; Souichi Adachi; Ikuya Usami; Masayuki Okada; Toshiyuki Kitoh; Mitsutaka Shiota; Yoshihiro Taniguchi; Akihiko Tanizawa; Mitsuhiko Nanbu; Keigo Hamahata; Hisanori Fujino; Kousaku Matsubara; Yoshihiro Wakazono; Tatsutoshi Nakahata
Journal:  Int J Hematol       Date:  2010-01-05       Impact factor: 2.490

Review 5.  Transitioning patients with immune thrombocytopenia to second-line therapy: Challenges and best practices.

Authors:  Adam Cuker
Journal:  Am J Hematol       Date:  2018-04-15       Impact factor: 10.047

6.  Splenectomy for immune thrombocytopenia: the evolution and preservation of treatment.

Authors:  Allison Remiker; Cindy Neunert
Journal:  Haematologica       Date:  2020-11-01       Impact factor: 9.941

7.  Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations.

Authors:  Monica Carpenedo; Erminia Baldacci; Claudia Baratè; Alessandra Borchiellini; Francesco Buccisano; Giuseppina Calvaruso; Federico Chiurazzi; Bruno Fattizzo; Gaetano Giuffrida; Elena Rossi; Francesca Palandri; Potito Rosario Scalzulli; Sergio Mario Siragusa; Angelantonio Vitucci; Francesco Zaja
Journal:  Ther Adv Hematol       Date:  2021-10-09

8.  Long-term results of laparoscopic splenectomy in pediatric chronic immune thrombocytopenic purpura.

Authors:  Dong Jin Kim; Jae Hee Chung
Journal:  Ann Surg Treat Res       Date:  2014-05-23       Impact factor: 1.859

9.  High Remission Rate of Chronic Immune Thrombocytopenia in Children: Result of 20-Year Follow-Up.

Authors:  Chae Young Kim; Eun Hye Lee; Hoi Soo Yoon
Journal:  Yonsei Med J       Date:  2016-01       Impact factor: 2.759

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.